These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38700282)

  • 1. Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics.
    Inokuchi T; Fukumoto Y; Lee G; Yokomizo Y; Tanaka K; Chosa M; Doi M; Tamaki N; Goto S; Ichikawa K; Kobayashi K
    J Diabetes Investig; 2024 Sep; 15(9):1202-1210. PubMed ID: 38700282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment.
    Baldassarre MPA; Di Dalmazi G; Coluzzi S; Carrieri F; Febo F; Centorame G; Cassino P; Piacentino L; Baroni MG; Consoli A; Formoso G
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892765
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings.
    Yamada H; Yoshida M; Funazaki S; Morimoto J; Tonezawa S; Takahashi A; Nagashima S; Masahiko K; Kiyoshi O; Hara K
    J Cardiovasc Dev Dis; 2023 Apr; 10(4):. PubMed ID: 37103055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.
    Yoneda C; Kobayashi J; Kuribayashi N
    Diabetol Int; 2024 Jul; 15(3):569-576. PubMed ID: 39101186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
    Kimura T; Katakura Y; Shimoda M; Kawasaki F; Yamabe M; Tatsumi F; Matsuki M; Iwamoto Y; Anno T; Fushimi Y; Kamei S; Kimura Y; Nakanishi S; Mune T; Kaku K; Kaneto H;
    Diabetes Obes Metab; 2023 Dec; 25(12):3632-3647. PubMed ID: 37646192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
    Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.
    Araki E; Terauchi Y; Watada H; Deenadayalan S; Christiansen E; Horio H; Kadowaki T
    Diabetes Obes Metab; 2021 Dec; 23(12):2785-2794. PubMed ID: 34472698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
    Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
    JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
    Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
    Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.
    Yabe D; Yamada Y; Kaku K; Nishida T; Sato T; Seino Y
    J Diabetes Investig; 2022 Jul; 13(7):1161-1174. PubMed ID: 35174649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
    Jain AB; Reichert SM; Amadid H; Braae UC; Bradley RM; Kim JW; Soo V; Yale JF
    Diabetes Obes Metab; 2024 May; 26(5):1799-1807. PubMed ID: 38468125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
    Seijas-Amigo J; Salgado-Barreira Á; Castelo-Dominguez R; Pérez-Álvarez MT; Ponce-Piñón B; Fernández-Silva M; Rodríguez-Barreiro M; Pereira-Pía M; Iglesias-Moreno JM; Gago-García M; Montáns-García R; Fernandez-Perez A; FragaGayoso D; Fernandez-Montenegro M; Riveiro-Barciela B; Rilla-Villar N; Cordero A; RodríguezMañero M; González-Juanatey JR
    Prim Care Diabetes; 2023 Aug; 17(4):366-372. PubMed ID: 37230813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
    Seino Y; Terauchi Y; Osonoi T; Yabe D; Abe N; Nishida T; Zacho J; Kaneko S
    Diabetes Obes Metab; 2018 Feb; 20(2):378-388. PubMed ID: 28786547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.